PRECISION PROTEIN NANOTHERAPY: TARGETING GLIOBLASTOMAS WITH ADVANCED TREATMENT STRATEGIES

Garima Joshi

doi:10.55640/

Open Access

PRECISION PROTEIN NANOTHERAPY: TARGETING GLIOBLASTOMAS WITH ADVANCED TREATMENT STRATEGIES

https://doi.org/10.55640/

PDF

Garima Joshi ¹ ,

⁴ Parul Institute of Pharmacy and Research, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, India

Abstract

"Precision Protein Nanotherapy: Targeting Glioblastomas with Advanced Treatment Strategies" explores the promising avenue of using protein nanoparticles for targeted therapy in glioblastomas, a highly aggressive form of brain cancer. This paper examines the potential of protein-based nanocarriers to overcome the challenges associated with conventional glioblastoma treatments, including limited drug penetration into the brain and systemic toxicity. By leveraging the unique properties of protein nanoparticles, such as their biocompatibility, stability, and tunable surface functionalities, researchers aim to enhance drug delivery specificity and efficacy while minimizing off-target effects. This review highlights recent advancements in protein nanoparticle-based drug delivery systems and discusses their potential applications in glioblastoma treatment, including targeted drug delivery, imaging, and combination therapy approaches. By harnessing the precision of protein nanotherapeutics, this research holds promise for improving the outcomes and quality of life for patients with glioblastomas.

Keywords

Protein nanoparticles, Glioblastoma, Targeted therapy

References

📄 Gao M, Mei D, Huo Y, Mao S. Effect of polysorbate 80 on the intranasal absorption and brain distribution of tetramethylpyrazine phosphate in rats. Drug delivery and translational research. 2019 Feb 15;9(1):311-8.

📄 Muankaew C, Loftsson T. Cyclodextrin‐based formulations: a non‐invasive platform for targeted drug delivery. Basic & clinical pharmacology & toxicology. 2018 Jan;122(1):46-55.

📄 21) Shah B, Khunt D, Misra M, Padh H. Formulation and in-vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting. Pharmaceutical research. 2018 Jan;35(1):1-0.

📄 Dayal P, Shaik MS, Singh M. Evaluation of different parameters that affect droplet‐size distribution from nasal sprays using the Malvern Spraytec®. Journal of pharmaceutical sciences. 2004 Jul 1;93(7):1725-42.

📄 Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. European Neuropsychopharmacology. 2013 Oct 1;23(10):1190-8.

📄 Ferreira, S. L. C. et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal. Chim. Acta 597, 179–186 (2007).

📄 Box, G. E. P. & Behnken, D. Some New Three Level Designs for the Study of Quantitative Variables. Technometrics 2, 455–475 (1960).

How to Cite

PRECISION PROTEIN NANOTHERAPY: TARGETING GLIOBLASTOMAS WITH ADVANCED TREATMENT STRATEGIES. (2024). Global Journal of Medical and Pharmaceutical Sciences, 3(04), 01-05. https://doi.org/10.55640/